Significant variables included HF/LVEF ≤ 40% (Cramér's V = 0.12, power = 89.53%) and the use of SGLT2 inhibitors (Cramér's V = 0.11, power = 81.58%). This evidence concerns the gene SLC5A2 and hydrops fetalis.